Welcome To
Target Systemic Mastocytosis
Comprehensive Peer-Developed Educational Resources
About Systemic Mastocytosis

Mission Statement
The mission of Target Systemic Mastocytosis (Target SM) is to provide rigorous, comprehensive educational resources about systemic mastocytosis to healthcare professionals who may encounter these patients in their practice. Blueprint Medicines organized and engaged the Target SM Committee, a group of physicians with expertise in systemic mastocytosis that represent a wide range of specialties. Educational resources were developed by Blueprint Medicines in collaboration with the Target SM Committee, and Blueprint Medicines provided funding to the committee for their time and expertise in developing this content.
What is Systemic Mastocytosis?
Clinical Perspectives
Systemic mastocytosis is a rare, clonal mast cell neoplasm driven by the KIT D816V mutation in ~95% of patients. In patients with systemic mastocytosis, abnormal mast cell activation and uncontrolled mast cell proliferation result in unpredictable, debilitating symptoms.1-4
To learn more about systemic mastocytosis, please click the link below and explore the “Systemic Mastocytosis: Disease State Overview” slide module.
References: 1. Vaes M et al. Front Med. 2017;4:110. 2. Jara-Acevedo M et al. Mod Pathol. 2015;28(8):1138-1149. 3. Garcia-Montero AC et al. Blood. 2006;108(7):2366-2372. 4. Jennings SV et al. Immunol Allergy Clin North Am. 2018;38(3):505-525.
Allergist/
Immunologist

Cem Akin,
MD, PHD
Systemic Mastocytosis Diagnosis and Treatment:
An Allergist/
Immunologist's Perspective

Allergist/
Immunologist

EXCERPT FROM DR. CEM AKIN'S PRESENTATION ON BEHALF OF BLUEPRINT MEDICINES AT AAAAI 2021

Hematologist/
Oncologist

Daniel Deangelo,
MD, PHD
Systemic Mastocytosis Diagnosis and Treatment:
A Hematologist/
Oncologist's Perspective

Pathologist

Tracy George,
MD
Systemic Mastocytosis Diagnosis and Treatment:
A Pathologist's Perspective

What is Systemic Mastocytosis
Systemic mastocytosis is a rare, clonal mast cell neoplasm driven by the KIT D816V mutation in ~95% of patients. In patients with systemic mastocytosis, abnormal mast cell activation and uncontrolled mast cell proliferation result in unpredictable, debilitating symptoms.1-4
To learn more about systemic mastocytosis, please click the link below and explore the “Systemic Mastocytosis: Disease State Overview” slide module.
References: 1. Vaes M et al. Front Med. 2017;4:110. 2. Jara-Acevedo M et al. Mod Pathol. 2015;28(8):1138-1149. 3. Garcia-Montero AC et al. Blood. 2006;108(7):2366-2372. 4. Jennings SV et al. Immunol Allergy Clin North Am. 2018;38(3):505-525.
Clinical Prespectives
Allergist/
Immunologist

Cem Akin,
MD, PHD
Systemic Mastocytosis Diagnosis and Treatment:
An Allergist/
Immunologist's Perspective

Allergist/
Immunologist

EXCERPT FROM DR. CEM AKIN'S PRESENTATION ON BEHALF OF BLUEPRINT MEDICINES AT AAAAI 2021

Hematologist/
Oncologist

Daniel Deangelo,
MD, PHD
Systemic Mastocytosis Diagnosis and Treatment:
A Hematologist/
Oncologist's Perspective

Pathologist

Tracy George,
MD
Systemic Mastocytosis Diagnosis and Treatment:
A Pathologist's Perspective


What is Systemic Mastocytosis?
Systemic mastocytosis is a rare, clonal mast cell neoplasm driven by the KIT D816V mutation in ~95% of patients. In patients with systemic mastocytosis, abnormal mast cell activation and uncontrolled mast cell proliferation result in unpredictable, debilitating symptoms.1-4
To learn more about systemic mastocytosis, please click the link below and explore the “Systemic Mastocytosis: Disease State Overview” slide module.
References: 1. Vaes M et al. Front Med. 2017;4:110. 2. Jara-Acevedo M et al. Mod Pathol. 2015;28(8):1138-1149. 3. Garcia-Montero AC et al. Blood. 2006;108(7):2366-2372. 4. Jennings SV et al. Immunol Allergy Clin North Am. 2018;38(3):505-525.
Clinical Perspectives
Systemic MastoCytosis
Diagnosis and Treatment:
An Allergist/
Immunologist’s
Perspective
Cem Akin, MD, PHD

Systemic MastoCytosis
Diagnosis and Treatment:
A Hematologist/
Oncologist’s Perspective
Daniel Deangelo, MD, PHD

Systemic MastoCytosis
Diagnosis and Treatment:
A Pathologist’s
Perspective
Tracy George, MD

Allergist/
Immunologist

EXCERPT FROM DR. CEM AKIN'S PRESENTATION ON BEHALF OF BLUEPRINT MEDICINES AT AAAAI 2021
